Investors should consider Hims & Hers Health (HIMS) as a high-growth opportunity, with the stock currently viewed as undervalued following recent market volatility. The company is projected to see significant revenue growth of up to 33% by 2026, bolstered by the Eucalyptus acquisition and a robust subscription model for GLP-1 weight loss treatments. While legal battles with Novo Nordisk (NVO) persist, the impact is expected to be minimal until at least 2029, providing a long runway for current operations. Diversification into new peptides like BPC-157 offers a secondary growth catalyst that protects against potential shifts in the weight loss market. Monitor the FDA approval of Eli Lilly’s (LLY) Retatrutide, as this next-generation drug may eventually disrupt the demand for current compounded semaglutide offerings.

Hims & Hers Health, Inc. (HIMS)

Hims is a direct-to-consumer (DTC) telehealth platform that provides subscription-based access to health and wellness products, including treatments for hair loss, sexual health, and weight loss.

• Volatility as the "Price of Admission": The stock recently experienced a significant +13.5% daily rally. The analyst argues that high volatility is necessary for high returns; an asset that can double in a year also has the potential to drop by 50%.
• Revenue Guidance & Growth:
  • Management guided for 15% to 24% revenue growth for 2026.
  • When including the Eucalyptus acquisition (expected early 2H 2026), which brings an estimated $450 million in Annual Recurring Revenue (ARR), the analyst projects actual growth could be between 24% and 33%.
  • The company maintains a Rule of 40 score of 43, indicating a healthy balance between growth and profitability.
• Competitive Moat vs. AI/SaaS:
  • Unlike Software-as-a-Service (SaaS) companies, Hims deals with physical products (drugs) and a complex backend network.
  • The "moat" consists of a network of 2,000+ prescribers (MDs and NPs) and data from 2.5 million customers.
  • The analyst claims you cannot "vibe code" (easily replicate with AI) a physical lab or a regulated medical network.
• Legal and Regulatory Outlook:
  • Novo Nordisk Lawsuit: Hims and Novo Nordisk agreed to extend a legal deadline to April 1. The analyst believes this will be dragged out in court until potentially 2029–2031, minimizing near-term impact.
  • The "Peptide" Defense: There is a legal debate over whether naturally occurring peptides (like GLP-1s) can be patented in the same way as traditional drugs.
  • RFK Jr. Influence: Mention of potential policy shifts (e.g., legalizing 14 peptides for compounding, including BPC-157) could open new massive revenue streams for Hims' compounding facilities.
• Weight Loss Strategy (GLP-1s):
  • Hims is aggressively selling 6-month prescriptions for $1,200 up-front (partnering with Klarna for financing).
  • This is seen as a strategic move to "lock in" revenue before the potential FDA approval of Retatrutide (a next-gen drug from Eli Lilly), which might make current Semaglutide offerings less desirable.

Takeaways

• Valuation: The analyst views the stock as "dirt cheap" at current levels, suggesting the recent sell-off to the $14 range was an overreaction by the market.
• Risk Mitigation: The business has zero "geopolitical risk" as it operates almost entirely within the U.S., and limited "AI displacement risk" due to its physical product fulfillment.
• Actionable Strategy: Investors should expect continued "FUD" (Fear, Uncertainty, and Doubt) regarding GLP-1 patents but focus on the underlying subscription growth and the expansion into new peptides like BPC-157.

Weight Loss & Peptides (Sector Theme)

The discussion highlights a shift in the weight loss drug landscape, moving from current GLP-1s to next-generation treatments and compounding opportunities.

• Semaglutide vs. Tirzepatide: The analyst notes that Semaglutide (Ozempic/Wegovy) is losing popularity compared to Tirzepatide (Mounjaro/Zepbound).
• Retatrutide: Identified as a "game changer" that could disrupt the current market once FDA-approved.
• Compounding Opportunity: If the regulatory environment shifts to allow more peptide compounding, Hims is positioned to benefit due to its existing infrastructure.

Takeaways

• Monitor FDA Approvals: Keep a close eye on the approval timeline for Retatrutide, as it may signal a peak in demand for current compounded Semaglutide products.
• Diversification: The potential legalization of a broader range of peptides (like BPC-157) suggests the "weight loss" theme is evolving into a broader "longevity and performance" theme.

Mentioned Tickers & Entities

• Hims & Hers Health (HIMS): Primary focus; bullish sentiment based on valuation and growth.
• Novo Nordisk (NVO): Mentioned regarding legal complaints and patent protection.
• Eli Lilly (LLY): Mentioned in the context of Tirzepatide and the upcoming Retatrutide.
• Klarna: Mentioned as a financing partner for Hims' high-ticket prescriptions.
• Eucalyptus: A key acquisition expected to boost Hims' 2026 revenue.
• Oddity Tech (ODD): Used as a negative contrast (bearish) due to a significant guidance miss.